Maciej Pacula from Acton, MA, age 37

Methods And Systems For Determining Autism Spectrum Disorder Risk
view source
US Patent:

20180348199, Dec 6, 2018
Filed:

Aug 6, 2018
Appl. No.:

16/055966
Inventors:

- Burlington NC, US
Doris Damian - Lexington MA, US
Maciej Pacula - Lexington MA, US
Mark A. DePristo - Lexington MA, US
Jeffrey R. Luber - Lexington MA, US
Assignee:

Laboratory Corporation of America Holdings - Burlington NC
International Classification:

G01N 33/49
G16H 50/20
G16H 50/30
G06F 19/00
G01N 33/68
Abstract:

In certain embodiments, the invention stems from the discovery that analysis of population distribution curves of metabolite levels in blood can be used to facilitate predicting risk of autism spectrum disorder (ASD) and/or to differentiate between ASD and non-ASD developmental delay (DD) in a subject. In certain aspects, information from assessment of the presence, absence, and/or direction (upper or lower) of a tail effect in a metabolite distribution curve is utilized to predict risk of ASD and/or to differentiate between ASD and DD.

Metabolic Markers Of Attention Deficit Hyperactivity Disorder
view source
US Patent:

20160231311, Aug 11, 2016
Filed:

Feb 9, 2016
Appl. No.:

15/019258
Inventors:

- Lexington MA, US
Doris Damian - Lexington MA, US
Maciej Pacula - Lexington MA, US
Mark A. DePristo - Lexington MA, US
International Classification:

G01N 33/50
A61K 31/165
A61K 31/137
A61K 31/4168
A61K 31/4458
A61K 31/138
Abstract:

Disclosed herein are methods for treating subjects having ADHD identifiable by levels of 3-IS in blood.

Methods And Systems For Determining Autism Spectrum Disorder Risk
view source
US Patent:

20160091480, Mar 31, 2016
Filed:

Sep 25, 2015
Appl. No.:

14/866791
Inventors:

- Lexington MA, US
Doris Damian - Lexington MA, US
Maciej Pacula - Lexington MA, US
Mark A. DePristo - Lexington MA, US
Jeffrey R. Luber - Lexington MA, US
International Classification:

G01N 33/49
Abstract:

In certain embodiments, the invention stems from the discovery that analysis of population distribution curves of metabolite levels in blood can be used to facilitate predicting risk of autism spectrum disorder (ASD) and/or to differentiate between ASD and non-ASD developmental delay (DD) in a subject. In certain aspects, information from assessment of the presence, absence, and/or direction (upper or lower) of a tail effect in a metabolite distribution curve is utilized to predict risk of ASD and/or to differentiate between ASD and DD.

Methods And Systems For Determining Autism Spectrum Disorder Risk
view source
US Patent:

20160091481, Mar 31, 2016
Filed:

Sep 29, 2015
Appl. No.:

14/869322
Inventors:

- Lexington MA, US
Doris Damian - Lexington MA, US
Maciej Pacula - Lexington MA, US
Mark A. DePristo - Lexington MA, US
International Classification:

G01N 33/49
G01N 33/68
G01N 33/82
H01J 49/00
Abstract:

In certain embodiments, the invention stems from the discovery that analysis of population distribution curves of metabolite levels in blood can be used to facilitate predicting risk of autism spectrum disorder (ASD) and/or to differentiate between ASD and non-ASD developmental delay (DD) in a subject. In certain aspects, information from assessment of the presence, absence, and/or direction (upper or lower) of a tail effect in a metabolite distribution curve is utilized to predict risk of ASD and/or to differentiate between ASD and DD.

Methods And Systems For Determining Autism Spectrum Disorder Risk
view source
US Patent:

20150293072, Oct 15, 2015
Filed:

Feb 27, 2015
Appl. No.:

14/633558
Inventors:

- Lexington MA, US
Doris Damian - Lexington MA, US
Maciej Pacula - Lexington MA, US
Mark A. DePristo - Lexington MA, US
International Classification:

G01N 33/487
H01J 49/00
Abstract:

In certain embodiments, the invention stems from the discovery that analysis of population distribution curves of metabolite levels in blood can be used to facilitate predicting risk of autism spectrum disorder (ASD) and/or to differentiate between ASD and non-ASD developmental delay (DD) in a subject. In certain aspects, information from assessment of the presence, absence, and/or direction (upper or lower) of a tail effect in a metabolite distribution curve is utilized to predict risk of ASD and/or to differentiate between ASD and DD.

Methods And Systems For Determining Autism Spectrum Disorder Risk
view source
US Patent:

20150294081, Oct 15, 2015
Filed:

Sep 22, 2014
Appl. No.:

14/493141
Inventors:

- Lexington MA, US
Doris Damian - Lexington MA, US
Maciej Pacula - Lexington MA, US
Mark A. DePristo - Lexington MA, US
Jeffrey R. Luber - Lexington MA, US
Stanley N. Lapidus - Lexington MA, US
International Classification:

G06F 19/00
G01N 33/49
Abstract:

In certain embodiments, the invention stems from the discovery that analysis of population distribution curves of metabolite levels in blood can be used to facilitate predicting risk of autism spectrum disorder (ASD) and/or to differentiate between ASD and non-ASD developmental delay (DD) in a subject. In certain aspects, information from assessment of the presence, absence, and/or direction (upper or lower) of a tail effect in a metabolite distribution curve is utilized to predict risk of ASD and/or to differentiate between ASD and DD.